Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gardasil Goes To FDA; Merck Hopes For Mid-Year Approval Of HPV Vaccine

Executive Summary

Merck could have a strong case for priority review of its human papillomavirus vaccine Gardasil

You may also be interested in...



GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements

GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated

Merck Initiates Gardasil Detailing; Campaign To Focus On Cancer Prevention

Merck has begun detailing its pending human papilloma virus vaccine Gardasil to non-routine vaccinators, the company reported Dec. 15 during an annual business review in Whitehouse Station, N.J

Merck Initiates Gardasil Detailing; Campaign To Focus On Cancer Prevention

Merck has begun detailing its pending human papilloma virus vaccine Gardasil to non-routine vaccinators, the company reported Dec. 15 during an annual business review in Whitehouse Station, N.J

Related Content

Topics

UsernamePublicRestriction

Register

PS046646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel